Clinical trial · Interventional
Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
NCT02279693CI-TRIAL-00074003PROSTRACKterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): feasibility problem
Summary
Brief summary (as posted)
This study evaluates the dose received by the prostate with in vivo dosimetry when delivering image guided radiation therapy (IGRT) associated with intensity modulated radiation therapy (IMRT) for patients with localized prostate cancer using two repositioning techniques: fiduciary markers or soft tissues.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CBCT | Other | — | UNRESOLVED |
| fiducial marker (kV imaging) | Other | — | UNRESOLVED |
| IGRT Associated With IMRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- CBCT
- description
- cone beam computed tomography (CBCT) repositioning
- interventionNames
- Other: CBCT
- Radiation: IGRT Associated With IMRT
- type
- OTHER
- label
- fiducial markers
- description
- kV imaging of fiducial marker repositioning
- interventionNames
- Other: fiducial marker (kV imaging)
- Radiation: IGRT Associated With IMRT
Primary outcomes (1)
- measure
- dosimetry (measurement of the absorbed dose, delivered to prostate, by ionizing radiation)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * male \> 18 years * carcinoma of the prostate histologically confirmed * OMS 0-1 * localized stage * favorable, intermediate and unfavorable groups according to NCCN or D'Amico classification * patients must have signed a written informed consent form * patients must be affiliated to a Social Health Insurance. Exclusion Criteria: * metastasis * indication for pelvic radiation * anticoagulant therapy * lateral or bilateral hip replacement * patient receiving an adult protective services * Patient unable to comply with the required medical follow-up for geographic, social or psychological reasons
References
Publications (0)
Data not yet available
No reference posted for this study.